Still Eyeing IPO, Quark Says Cost Expectations for Rx Pipeline Exceed $54M
January 27, 2011
Still Eyeing IPO, Quark Says Cost Expectations for Rx Pipeline Exceed $54M
The company hopes to raise enough capital in the IPO to pay for that bill, which covers phase I and II trials for its lead candidates. It also said R&D costs decreased over the first nine months of 2010 while revenues rose for the period year over year.
Full-text access for premium subscribers only.
Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.
New to GenomeWeb? Register here quickly.
Related Stories
- Quark to Run Phase IIa Trial of RNAi Drug in Glaucoma
May 3, 2012 / Gene Silencing News - Quark Still Sees IPO as a Possibility as Phase II Trials Near Completion
February 9, 2012 / Gene Silencing News - RNAi Drugs Field Sees Candidate Failures as More Drugs Enter the Clinic
November 17, 2011 / Gene Silencing News - Quark Scuttles IPO Plans for the Second Time
September 29, 2011 / Gene Silencing News - Lundbeck, Debiopharm Join List of Pharmas Looking to RNAi
February 3, 2011 / Gene Silencing News